Carl Stubbings Chief Executive Officer and Managing Director 

Carl Stubbings, BSc, joined Sienna’s Board in December 2011. Carl has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics, one of the world’s largest pathology laboratories. In July 2012, Carl moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC).

More recently he has been assisting several Australian biotech companies with their commercialisation strategies. These companies include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercialising anti-viral small molecule therapies.

Carl was previously a Non-executive Director of ASX listed medical device company Analytica Medical Limited (ASX:ALT), until November 2017.

Tony Di Pietro Chief Financial Officer & Company Secretary 

Tony commenced in the role of Chief Financial Officer in November 2014 and was appointed Company Secretary in February 2015. He is a chartered accountant with significant corporate accounting experience, gained both in Australia and the UK. He also holds a Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia. Tony’s experience spans many industries including biotechnology, resources, banking, patient transport, security and parking, having been employed by companies such as BHP Ltd (now BHP Billiton Ltd), ExxonMobil Ltd, HSBC Ltd and Wilson Group. Prior to his appointment at Sienna, Tony was employed at Acrux Limited, where he was a key member of management for more than 10 years. During this period, Acrux transitioned from a small loss-making public company to an ASX listed company generating significant profits.

Dr Peter French Strategic Technology Advisor 

Peter has over 40 years’ experience in cell and molecular biology and has published across a wide range of areas, including oncology, immunology, microbiology and neuroscience.

Dr French was a Director of several biotech companies in Australia and the US, including Cryosite, Probiomics Ltd., Benetic Biopharma, and most recently served as CEO of Sevident.

Peter is focussed on sourcing, evaluating and ultimately acquiring new technologies that can become products in Sienna’s development and commercialisation pipeline. Peter’s work ensures that Sienna has both a near-term and a long-term strategy for technology evolution and growth.

Dr Wayne Jensen Research & Development Director 

Wayne has over 25 years’ experience in the IVD medical device industry, with a track record in developing IVD products from inception to completion, enabling in-house production and international market release.

He also has deep experience in partnered product development as a conduit to market release with international IVD companies, including Abbott, Roche, Siemens, Beckman Coulter and Sigma. He previously held roles in research and development with companies including Universal Biosensors and Thermo Fisher Scientific.

As the head of R&D across the Sienna portfolio, Wayne manages the R&D strategic planning and implementation, including the integration of new technologies acquired or in-licensed by Sienna. He and his team are currently developing and executing plans to manufacture the SIENNET ™ product line.


Sign up for updates